Company News
March 09 ASep Healthcare in discussion with third parties to commercialise Tournistrip in key markets EU markets
Tournistrip, the only tourniquet to have been clinically trialed
78% of phlebotomists actually preferred Tournistrip to their current tourniquet
A high proportion of conventional tourniquets are contaminated with blood and bacterial pathogens
The average reusable Tourniquet is owned for 1.86 years
Tournistrip's unique design and construction mean that it is truly single use